Laxogenin

Laxogenin ((25R)-3β-Hydroxy-5α-spirostan-6-one; 6-Oxotigogenin) is an orally active myostatin (myostatin) inhibitor. Laxogenin promotes myogenesis and enhances the formation and maturation of myotubes. Laxogenin downregulates ROS. When added to the culture medium for cultured meat production, Laxogenin improves the texture, quality and nutritional value of cultured meat. Laxogenin reduces the average number of tumors in a two-stage mouse lung carcinogenesis model. Laxogenin can be used in research related to myogenesis and lung cancer^[1][2]. In Vitro:Laxogenin (10 nM) promotes the differentiation of bovine bone marrow mesenchymal stem cells (MSCs) through the following mechanisms: increasing creatine kinase activity by 11%, upregulating the expression of myogenic markers, downregulating the expression of myostatin (MSTN), reducing reactive oxygen species (ROS) levels by 18%, and increasing myotube size^[1].
Laxogenin (10 nM) promotes the differentiation of porcine mesenchymal stem cells (MSCs) through the following mechanisms: increasing creatine kinase activity by up to 18%, upregulating the expression of myogenic markers, downregulating MSTN expression, and reducing ROS levels by 7%^[1].
Laxogenin (10 nM) promotes the differentiation of chicken bone marrow mesenchymal stem cells (MSCs) through the following mechanisms: increasing creatine kinase activity by 9-12%, upregulating the expression of myogenic markers, reducing the expression of MSTN, and decreasing reactive oxygen species (ROS) levels by 37%^[1].
Laxogenin (10 nM) promotes the differentiation of C2C12 cells by increasing myotube size, upregulating MYH protein expression, enhancing creatine kinase activity by 9-19%, and upregulating the expression of myogenic markers over a 6-day differentiation period^[1].
Laxogenin (10 nM) inhibits the MSTN signaling pathway in C2C12 cells, reduces ROS levels by approximately 8%, and upregulates the expression of antioxidant factors to promote cell differentiation^[1].
Laxogenin (Compound 3) (100 μg/mL; pre-incubated for 1 h prior to the addition of ³²Pi/TPA, followed by 4 h of incubation) inhibits TPA-induced ³²Pi incorporation into phospholipids of HeLa cells by 82.1%^[2].